Is SGMO or IMNN more profitable?

Imunon has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. Imunon's return on equity of -358.01% beat Sangamo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sangamo Therapeutics -310.81% -2,662.06% -132.12% Imunon N/A -358.01% -132.91%

Which has higher earnings and valuation, BRNS or IMNN?

Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Barinthus Biotherapeutics N/A N/A -$66.43M -$1.03 N/A Imunon N/A N/A -$14.49M -$3.83 N/A

Is BRNS or IMNN more profitable?

Barinthus Biotherapeutics' return on equity of -59.15% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Barinthus Biotherapeutics N/A -59.15% -43.80% Imunon N/A -358.01% -132.91%

Which has preferable valuation and earnings, CNTX or IMNN?

Context Therapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Context Therapeutics N/A N/A -$36.12M -$0.48 N/A Imunon N/A N/A -$14.49M -$3.83 N/A

Is CNTX or IMNN more profitable?

Context Therapeutics' return on equity of -82.06% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -82.06% -72.74% Imunon N/A -358.01% -132.91%

Which has better earnings and valuation, QNCX or IMNN?

Imunon is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quince Therapeutics N/A N/A -$83.98M -$156.71 N/A Imunon N/A N/A -$14.49M -$3.83 N/A

Is QNCX or IMNN more profitable?

Quince Therapeutics' return on equity of 0.00% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A N/A -133.84% Imunon N/A -358.01% -132.91%

Does the media prefer QNCX or IMNN?

In the previous week, Quince Therapeutics had 2 more articles in the media than Imunon. MarketBeat recorded 4 mentions for Quince Therapeutics and 2 mentions for Imunon. Quince Therapeutics' average media sentiment score of 0.67 beat Imunon's score of 0.44 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Imunon 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, IMNN or EVAX?

Evaxion A/S has higher revenue and earnings than Imunon. Evaxion A/S is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Imunon N/A N/A -$14.49M -$3.83 N/A Evaxion A/S $7.53M 3.77 -$7.71M -$1.21 N/A

Is IMNN or EVAX more profitable?

Evaxion A/S's return on equity of -61.43% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Imunon N/A -358.01% -132.91% Evaxion A/S N/A -61.43% -34.23%

Does the media favor IMNN or EVAX?

In the previous week, Evaxion A/S had 1 more articles in the media than Imunon. MarketBeat recorded 3 mentions for Evaxion A/S and 2 mentions for Imunon. Imunon's average media sentiment score of 0.44 beat Evaxion A/S's score of 0.00 indicating that Imunon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Imunon 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evaxion A/S 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Imunon (IMNN) Competitors

$1.12 -0.12 (-9.68%)

Closing price 04:00 PM Eastern

Extended Trading

$1.22 +0.10 (+8.93%)

As of 06:04 PM Eastern

Compare

IMNN vs. SGMO, BRNS, CNTX, QNCX, and EVAX

Should you buy Imunon stock or one of its competitors? Imunon's main competitors and comparable companies include Sangamo Therapeutics (SGMO), Barinthus Biotherapeutics (BRNS), Context Therapeutics (CNTX), Quince Therapeutics (QNCX), and Evaxion A/S (EVAX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Imunon compare to Sangamo Therapeutics?

Sangamo Therapeutics (NASDAQ:SGMO) and Imunon (NASDAQ:IMNN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

Imunon has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. Imunon's return on equity of -358.01% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Imunon	N/A	-358.01%	-132.91%

Sangamo Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 7,332.43%. Imunon has a consensus target price of $10.00, suggesting a potential upside of 706.45%. Given Sangamo Therapeutics' higher possible upside, analysts plainly believe Sangamo Therapeutics is more favorable than Imunon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Imunon has lower revenue, but higher earnings than Sangamo Therapeutics. Imunon is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
Imunon	N/A	N/A	-$14.49M	-$3.83	N/A

56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 4.5% of Imunon shares are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by company insiders. Comparatively, 2.8% of Imunon shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Sangamo Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, Imunon has a beta of 2.01, suggesting that its stock price is 101% more volatile than the broader market.

In the previous week, Imunon had 2 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 2 mentions for Imunon and 0 mentions for Sangamo Therapeutics. Imunon's average media sentiment score of 0.44 beat Sangamo Therapeutics' score of 0.00 indicating that Imunon is being referred to more favorably in the news media.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
Imunon	Neutral

Summary

Sangamo Therapeutics and Imunon tied by winning 7 of the 14 factors compared between the two stocks.

How does Imunon compare to Barinthus Biotherapeutics?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Imunon (NASDAQ:IMNN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	N/A	N/A	-$66.43M	-$1.03	N/A
Imunon	N/A	N/A	-$14.49M	-$3.83	N/A

Barinthus Biotherapeutics' return on equity of -59.15% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%
Imunon	N/A	-358.01%	-132.91%

Barinthus Biotherapeutics has a beta of -0.37, meaning that its stock price is 137% less volatile than the broader market. Comparatively, Imunon has a beta of 2.01, meaning that its stock price is 101% more volatile than the broader market.

In the previous week, Imunon had 2 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 2 mentions for Imunon and 0 mentions for Barinthus Biotherapeutics. Imunon's average media sentiment score of 0.44 beat Barinthus Biotherapeutics' score of 0.00 indicating that Imunon is being referred to more favorably in the news media.

Company	Overall Sentiment
Barinthus Biotherapeutics	Neutral
Imunon	Neutral

Barinthus Biotherapeutics presently has a consensus price target of $4.00, indicating a potential upside of 440.47%. Imunon has a consensus price target of $10.00, indicating a potential upside of 706.45%. Given Imunon's higher possible upside, analysts clearly believe Imunon is more favorable than Barinthus Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 4.5% of Imunon shares are held by institutional investors. 8.5% of Barinthus Biotherapeutics shares are held by insiders. Comparatively, 2.8% of Imunon shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Imunon beats Barinthus Biotherapeutics on 6 of the 11 factors compared between the two stocks.

How does Imunon compare to Context Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and Imunon (NASDAQ:IMNN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 4.8% of Context Therapeutics shares are owned by company insiders. Comparatively, 2.8% of Imunon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Context Therapeutics' return on equity of -82.06% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-82.06%	-72.74%
Imunon	N/A	-358.01%	-132.91%

Context Therapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A
Imunon	N/A	N/A	-$14.49M	-$3.83	N/A

In the previous week, Imunon had 2 more articles in the media than Context Therapeutics. MarketBeat recorded 2 mentions for Imunon and 0 mentions for Context Therapeutics. Imunon's average media sentiment score of 0.44 beat Context Therapeutics' score of 0.00 indicating that Imunon is being referred to more favorably in the news media.

Company	Overall Sentiment
Context Therapeutics	Neutral
Imunon	Neutral

Context Therapeutics has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market. Comparatively, Imunon has a beta of 2.01, indicating that its share price is 101% more volatile than the broader market.

Context Therapeutics presently has a consensus price target of $6.17, suggesting a potential upside of 1,732.59%. Imunon has a consensus price target of $10.00, suggesting a potential upside of 706.45%. Given Context Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Context Therapeutics is more favorable than Imunon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Context Therapeutics beats Imunon on 8 of the 13 factors compared between the two stocks.

How does Imunon compare to Quince Therapeutics?

Quince Therapeutics (NASDAQ:QNCX) and Imunon (NASDAQ:IMNN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

Imunon is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A
Imunon	N/A	N/A	-$14.49M	-$3.83	N/A

Quince Therapeutics' return on equity of 0.00% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-133.84%
Imunon	N/A	-358.01%	-132.91%

30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 5.6% of Quince Therapeutics shares are owned by insiders. Comparatively, 2.8% of Imunon shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Quince Therapeutics has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market. Comparatively, Imunon has a beta of 2.01, meaning that its share price is 101% more volatile than the broader market.

In the previous week, Quince Therapeutics had 2 more articles in the media than Imunon. MarketBeat recorded 4 mentions for Quince Therapeutics and 2 mentions for Imunon. Quince Therapeutics' average media sentiment score of 0.67 beat Imunon's score of 0.44 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Imunon	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Quince Therapeutics presently has a consensus price target of $206.71, indicating a potential upside of 635.64%. Imunon has a consensus price target of $10.00, indicating a potential upside of 706.45%. Given Imunon's higher possible upside, analysts clearly believe Imunon is more favorable than Quince Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.62
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Quince Therapeutics beats Imunon on 9 of the 14 factors compared between the two stocks.

How does Imunon compare to Evaxion A/S?

Imunon (NASDAQ:IMNN) and Evaxion A/S (NASDAQ:EVAX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

Imunon currently has a consensus price target of $10.00, suggesting a potential upside of 706.45%. Evaxion A/S has a consensus price target of $11.00, suggesting a potential upside of 249.21%. Given Imunon's higher probable upside, equities analysts clearly believe Imunon is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Imunon has a beta of 2.01, suggesting that its share price is 101% more volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

4.5% of Imunon shares are owned by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are owned by institutional investors. 2.8% of Imunon shares are owned by insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Evaxion A/S's return on equity of -61.43% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Imunon	N/A	-358.01%	-132.91%
Evaxion A/S	N/A	-61.43%	-34.23%

In the previous week, Evaxion A/S had 1 more articles in the media than Imunon. MarketBeat recorded 3 mentions for Evaxion A/S and 2 mentions for Imunon. Imunon's average media sentiment score of 0.44 beat Evaxion A/S's score of 0.00 indicating that Imunon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Imunon	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evaxion A/S	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Evaxion A/S has higher revenue and earnings than Imunon. Evaxion A/S is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Imunon	N/A	N/A	-$14.49M	-$3.83	N/A
Evaxion A/S	$7.53M	3.77	-$7.71M	-$1.21	N/A

Summary

Evaxion A/S beats Imunon on 10 of the 14 factors compared between the two stocks.

Get Imunon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMNN vs. The Competition

Export

Metric	Imunon	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.28M	$3.81B	$7.10B	$13.40B
Dividend Yield	N/A	3.65%	2.54%	17.38%
P/E Ratio	-0.29	13.29	273.96	26.22
Price / Sales	N/A	1,289.01	634.66	101.27
Price / Cash	N/A	39.04	27.22	34.74
Price / Book	0.49	16.78	11.09	6.35
Net Income	-$14.49M	-$23.16M	$3.49B	$381.26M
7 Day Performance	-16.10%	-4.05%	-2.30%	-0.61%
1 Month Performance	-29.11%	-12.06%	-7.05%	-4.84%
1 Year Performance	-78.59%	14.68%	5.65%	1.12%

Imunon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
IMNN Imunon	2.1733 of 5 stars	$1.12 -9.7%	$10.00 +792.9%	-76.9%	$6.28M	N/A	N/A	20
SGMO Sangamo Therapeutics	1.0076 of 5 stars	$0.07 flat	$5.50 +7,332.4%	N/A	$30.66M	$39.55M	N/A	480
BRNS Barinthus Biotherapeutics	1.7843 of 5 stars	$0.74 flat	$4.00 +440.5%	N/A	$30.23M	N/A	N/A	107
CNTX Context Therapeutics	2.0902 of 5 stars	$0.32 -2.2%	$6.17 +1,833.1%	-69.4%	$29.98M	N/A	N/A	15
QNCX Quince Therapeutics	3.4711 of 5 stars	$31.17 +7.5%	$206.71 +563.2%	-91.5%	$29.50M	N/A	N/A	38

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMNN) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Imunon (IMNN) Competitors

IMNN vs. SGMO, BRNS, CNTX, QNCX, and EVAX

How does Imunon compare to Sangamo Therapeutics?

Summary

How does Imunon compare to Barinthus Biotherapeutics?

Summary

How does Imunon compare to Context Therapeutics?

Summary

How does Imunon compare to Quince Therapeutics?

Summary

How does Imunon compare to Evaxion A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNN vs. The Competition

Imunon Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Imunon (IMNN) Competitors

IMNN vs. SGMO, BRNS, CNTX, QNCX, and EVAX

How does Imunon compare to Sangamo Therapeutics?

Is SGMO or IMNN more profitable?

Do analysts recommend SGMO or IMNN?

Which has stronger earnings & valuation, SGMO or IMNN?

Do institutionals and insiders hold more shares of SGMO or IMNN?

Which has more volatility and risk, SGMO or IMNN?

Does the media prefer SGMO or IMNN?

Summary

How does Imunon compare to Barinthus Biotherapeutics?

Which has higher earnings and valuation, BRNS or IMNN?

Is BRNS or IMNN more profitable?

Which has more volatility & risk, BRNS or IMNN?

Does the media prefer BRNS or IMNN?

Do analysts rate BRNS or IMNN?

Do insiders and institutionals have more ownership in BRNS or IMNN?

Summary

How does Imunon compare to Context Therapeutics?

Do insiders & institutionals hold more shares of CNTX or IMNN?

Is CNTX or IMNN more profitable?

Which has preferable valuation and earnings, CNTX or IMNN?

Does the media prefer CNTX or IMNN?

Which has more volatility & risk, CNTX or IMNN?

Do analysts prefer CNTX or IMNN?

Summary

How does Imunon compare to Quince Therapeutics?

Which has better earnings and valuation, QNCX or IMNN?

Is QNCX or IMNN more profitable?

Do insiders & institutionals believe in QNCX or IMNN?

Which has more volatility and risk, QNCX or IMNN?

Does the media prefer QNCX or IMNN?

Do analysts recommend QNCX or IMNN?

Summary

How does Imunon compare to Evaxion A/S?

Do analysts rate IMNN or EVAX?

Which has more volatility and risk, IMNN or EVAX?

Do insiders and institutionals hold more shares of IMNN or EVAX?

Is IMNN or EVAX more profitable?

Does the media favor IMNN or EVAX?

Which has preferable earnings & valuation, IMNN or EVAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNN vs. The Competition

Imunon Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools